Show simple item record

dc.contributor.authorMol, Ben W.
dc.contributor.authorJacobsson, Bo
dc.contributor.authorGrobman, William
dc.contributor.authorMoley, Kelle
dc.contributor.authorFIGO Working Group for Preterm Birth
dc.date.accessioned2021-10-06T20:53:00Z
dc.date.available2021-10-06T20:53:00Z
dc.date.issued2021-10-01
dc.identifier.citationMol , B W , Jacobsson , B , Grobman , W , Moley , K & FIGO Working Group for Preterm Birth 2021 , ' FIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologies ' , International Journal of Gynecology and Obstetrics , vol. 155 , no. 1 , pp. 13-15 . https://doi.org/10.1002/ijgo.13834en
dc.identifier.issn0020-7292
dc.identifier.otherPURE: 201501457
dc.identifier.otherPURE UUID: b9a0e77b-8d02-4251-8243-ab75dc360a97
dc.identifier.otherScopus: 85115059244
dc.identifier.otherJisc: d3cdd20433334158ada61a9bf8163f35
dc.identifier.urihttps://hdl.handle.net/2164/17278
dc.descriptionFunding Information: This work has been supported by grants from March of Dimes to the FIGO Working Group for Preterm Birth. This document is endorsed by FIGO Committee for Reproductive Medicine, Endocrinology and Infertility, and was discussed at their committee meeting on March 11, 2021. Funding Information: Ben W. Mol reports an investigator grant from NHMRC; consultancy for ObsEva; and research funding from Guerbet, Ferring, and Merck KGaA. Bo Jacobbson reports Research grants from Swedish Research Council, Norwegian Research Council, March of Dimes, Burroughs Wellcome Fund and the US National Institute of Health; clinical diagnostic trials on NIPT with Ariosa (completed), Natera (ongoing), Vanadis (completed) and Hologic (ongoing) with expendidures reimbused per patient; clinical probiotic studies with product provided by FukoPharma (ongoing, no funding) and BioGaia (ongoing; also provided a research grant for the specific study); collaboration in IMPACT study where Roche, Perkin Elmer and Thermo Fisher provided reagents to PLGF analyses; coordination of scientific conferences and meetings with commercial partners as such as NNFM 2015, ESPBC 2016 and a Nordic educational meeting about NIPT and preeclampsia screening. Bo Jacobbson is also Chair of the FIGO Working Group for Preterm Birth and the European Association of Perinatal Medicine's special interest group of preterm delivery; steering group member of Genomic Medicine Sweden; chairs the Genomic Medicine Sweden complex diseases group; and is Swedish representative in the Nordic Society of Precision Medicine. William Grobman and Kelle Moley report no conflicts of interest.en
dc.format.extent3
dc.language.isoeng
dc.relation.ispartofInternational Journal of Gynecology and Obstetricsen
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.https://creativecommons.org/licenses/by/4.0/en
dc.subjectassisted reproductive technologyen
dc.subjectchild outcomeen
dc.subjectpreterm deliveryen
dc.subjectsingle embryo transferen
dc.subjectR Medicineen
dc.subjectObstetrics and Gynaecologyen
dc.subjectOtheren
dc.subject.lccRen
dc.titleFIGO good practice recommendations on reduction of preterm birth in pregnancies conceived by assisted reproductive technologiesen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1002/ijgo.13834
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85115059244&partnerID=8YFLogxKen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record